Beneficial and harmful consequences of prepartum and postpartum antidepressant exposure

Corrado Barbui, Giovanni Ostuzzi

Department of Public Health and Community Medicine, Section of Psychiatry, WHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation, University of Verona, Verona, Italy

Correspondence to Corrado Barbui, corrado.barbui@univr.it

SETTING THE SCENE

Since women are twice as likely as men to experience depression, and depression mainly occurs during their reproductive years, high rates of depression during pregnancy and postpartum are expected. Epidemiological data suggest that the prevalence of major depression in pregnant women is in the range of 3–5%, and the combined prevalence of major and minor depression can reach 8–11%. Postpartum depression, which indicates a major depressive episode that occurs within the first 4 weeks after delivery or, using broader clinical criteria, within the first year after childbirth, may affect up to 13% of women.

As a consequence, a relevant and growing number of women are exposed to antidepressants (ADs) during pregnancy, after delivery and over the following months. On average, 1–8% of women receive AD medication during pregnancy, with higher prevalence of use during the first trimester. In the USA, a recent study showed that prenatal visits associated with AD prescriptions had increased from 0.7% (2002–2006) to 2.1% (2007–2010). In Denmark, a 16-fold increase in exposure rates between 1997 and 2010 was observed, from a rate of 0.2% in 1997 to 3.2% in 2010. After delivery and during the first year after childbirth the prevalence of AD prescriptions may steadily increase, as recently suggested by a Danish population-based prevalence study. The combination of depression and AD use during pregnancy and postpartum has been associated with harmful consequences in terms of neonatal and child development outcomes.

THE PROBLEM

An increased risk of physical and emotional/behavioural problems has consistently been observed in the offspring of mothers suffering from depression in the perinatal period. Probably, complex interactions between several pathways may explain this phenomenon, including biological mechanisms (eg, fetal exposure to maternal stress hormones), behavioural and emotional features (eg, poorer prenatal care and attachment style of depressed mothers) and genetic predisposition transmitted to the offspring. In addition to depression during pregnancy and postpartum, exposure to ADs is another major concern.

From a clinical point of view, treatment of depression with ADs during pregnancy and postpartum raises two challenging questions: in such a special population is efficacy of ADs similar as compared with the general population? Is the potentially beneficial effect of ADs for the mother outweighed by harmful consequences for the newborn as ADs cross the placenta and are present in amniotic fluid and mother’s milk?

THE SELECTED STUDIES

In this issue of EBMH, three studies are reviewed that expand current knowledge on the efficacy of ADs in women with postpartum depression, risk of pulmonary hypertension and risk of autism spectrum disorders in the offspring of women exposed to AD in pregnancy. Of note, one study employed a cohort design, while the other two are systematic reviews of randomised or observational studies (table 1).

BEFfitial EFFECTS OF ANTIDEPRESSANTS DURING PREGNANCY AND POSTPARTUM

Whether ADs are effective in treating depression in pregnant women cannot be directly assessed by means of randomised trials, as these would be deemed as unethical. It can only be indirectly inferred from randomised trials performed in general populations of individuals with major depression. These studies always exclude pregnant women and usually lump together data on men and women. However, assuming that pregnant women have a similar response to AD treatment as compared with the general population, randomised evidence suggests that the average benefit of these drugs is of small magnitude although it is possible that current approaches to estimation of the benefits of AD treatments may underestimate their clinical significance. Roughly, 53 of 100 depressed patients treated with an AD respond to treatment, as compared with 42 of 100 depressed patients treated with placebo, which yields an absolute difference of 11 patients out of 100. We additionally know that AD–placebo differences increase with increasing baseline severity and the difference becomes large enough to be clinically important only in moderate-to-severe major depression. Based on this indirect evidence, therefore, it is generally assumed that AD drugs are effective in treating moderate-to-severe depression in pregnant women.

It is true that there is no randomised data in pregnant women; however, in the postnatal period more robust evidence is available and it has recently been systematically reviewed by De Crescenzo et al. Out of six included studies, only three compared one selective serotonin reuptake inhibitor (SSRI) with placebo. Of these three studies, information on responders was available in two studies only: overall, 25% of depressed women treated with an SSRI responded to treatment, as compared with only 15% of depressed women treated with placebo. This yielded an absolute difference of 11% (95% CI 4% to 26%). In addition, when compared with psychological treatments, pharmacotherapy with SSRIs failed to show any significant difference.

Table 1 Main characteristics of three recent studies which investigated the beneficial and harmful consequences of prepartum and postpartum antidepressant exposure

<table>
<thead>
<tr>
<th>Study</th>
<th>Exposure</th>
<th>Outcome</th>
<th>Study design</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hviid et al</td>
<td>Pregnancy</td>
<td>Autism</td>
<td>Observational study (626 875 children)</td>
</tr>
<tr>
<td>Grigoriadis et al</td>
<td>Pregnancy</td>
<td>Pulmonary hypertension</td>
<td>Systematic review of seven observational studies (for characteristics of included studies, see <a href="http://www.bmj.com/content/suppl/2014/01/14/bmj.4932.DC2/griol14934.ww1_default.pdf">http://www.bmj.com/content/suppl/2014/01/14/bmj.4932.DC2/griol14934.ww1_default.pdf</a>)</td>
</tr>
<tr>
<td>De Crescenzo et al</td>
<td>Postpartum</td>
<td>Depressive symptoms</td>
<td>Systematic review of six randomised studies (595 patients)</td>
</tr>
</tbody>
</table>
It is striking to note that only few randomised trials have been conducted in this patient population, with very small sample size. This would lead to the conclusion that direct evidence on the efficacy of ADs in postpartum depression is virtually absent. However, putting these findings into the wider context of the whole evidence base on the efficacy of ADs in major depression, it seems interesting to note that the magnitude of AD effect, in terms of absolute risk difference (ARD), is similar between women with postpartum depression and the general population, and that lack of statistical significance in studies conducted in postpartum depression is likely the consequence of a power problem. Clinically, therefore, current best evidence would indicate that women with postpartum depression have a similar response to AD treatment as compared with the general population.

HARMFUL EFFECTS OF ANTIDEPRESSANTS DURING PREGNANCY: NEONATAL OUTCOMES

It has been noted that ADs are the most studied drugs during pregnancy, with more than 30000 neonatal outcomes following exposure during pregnancy documented in the peer-reviewed literature. The results of these studies are sometimes conflicting because of different interpretation of statistical versus clinical significance. However, in terms of major malformations, no specific pattern has been consistently associated with ADs, with the possible exception of paroxetine and cardiac malformations. It is generally reported that AD exposure may be associated with a significant increased risk of spontaneous abortion, preterm birth and infants born weighing less than 2500 g.

In addition, there might be a possible increased risk of persistent pulmonary hypertension of the newborn, but this finding is rather controversial. Recently, in order to expand current knowledge on this harmful outcome, Grigoriadis et al carried out a systematic review and meta-analysis of observational studies that examined the risk for persistent pulmonary hypertension of the newborn associated with antenatal AD exposure. Seven studies were included in the quantitative analysis. It was found that while exposure to SSRIs in early pregnancy was not associated with persistent pulmonary hypertension of the newborn (data from three studies), exposure in late pregnancy was associated with more than a twofold increase (five studies). Effects were not significant for any of the moderator variables examined, including study design, congenital malformations and meconium aspiration.

As is often the case with systematic reviews and meta-analyses, the main limitations are those of the original studies, which have been clearly analysed by the study authors. An additional concern, when meta-analytical techniques are applied, is whether pooling is appropriate. Studies must be homogeneous in terms of populations, exposure variables, comparisons and outcomes. This is a challenging issue when observational studies are pooled, as their design may markedly differ in relation to the different sources of data that are used. If studies are not similar, then heterogeneity is usually detected by visually checking in the forest plot the degree of overlap of the CIs around the point estimates calculated for each included studies. Additionally, heterogeneity may be investigated statistically. In this analysis, substantial heterogeneity was detected, despite a small number of included studies, which might suggest caution in pooling data. The reasons for this significant heterogeneity remains partially unknown, as the characteristics of the primary studies did not allow proper evaluation of a number of potential sources, including differences in the definition of early versus late exposure to SSRIs, maternal obesity, preterm birth and other factors.

Clinically, the statistically significant increased risk should be interpreted taking into account that persistent pulmonary hypertension is a relatively rare outcome, affecting on average 1.9/1000 newborns. Therefore, considering an increased relative risk of 2.5, as reported by this meta-analysis, it is possible to estimate an absolute risk, associated with SSRI exposure, of 1.9×2.5, which is 4.75, and an ARD of 4.75–1.9, which is 2.85/1000 newborns (ie, 0.285% or 0.00285). The inverse of the ARD (ie, 1/ARD) provides the number of women that need to be exposed to SSRIs during pregnancy to have one additional newborn with pulmonary hypertension, which are 351 (ie, 1/0.00285). In other words, a doctor would need to treat with SSRIs 351 pregnant women to have one additional newborn with pulmonary hypertension. These numbers prompted the authors to cautiously conclude that although the statistical association was significant, clinically the absolute risk of persistent pulmonary hypertension of the newborn remained low even in the context of late exposure to SSRIs.

HARMFUL EFFECTS OF ANTIDEPRESSANTS DURING PREGNANCY: CHILD DEVELOPMENT OUTCOMES

While the majority of studies on ADs during pregnancy are focused on teratogenic effects, delivery complications and neonatal toxicity, current knowledge on the potential harmful effects on child development, including autism spectrum disorders (ASDs) and emotional or behavioural problems in infancy and adolescence, are very unsatisfactory. Recently, a research team from Denmark performed a large population-based and register-based prospective cohort study to shed further light on this compelling issue. Researchers included only singleton births in a 10-year period, and excluded conditions associated with an increased risk of ASDs (eg, congenital rubella syndrome or some genetic disorders in parents). Information on a number of potential confounders was additionally collected (eg, maternal psychiatric diagnosis, age at the onset of pregnancy, parity, etc). Children were prospectively followed from birth until 5–10 years of age. Out of a total study cohort of 626 875 live births, 6068 children (1.0%) were exposed to SSRIs during pregnancy. In terms of risk of developing ASD, children of women exposed to SSRIs before and during pregnancy were more likely to receive a diagnosis of ASD. However, this significant association disappeared after adjusting for the following variables: mother’s age at birth, country of origin, place of residence, parity, psychiatric diagnoses before delivery, other drug use during pregnancy, smoking status during pregnancy, employment status and level of education. Similar results were found with children of women exposed to SSRI only during pregnancy.

In the present observational study, considering that the reference category was constituted by women with no SSRI exposure, confounding by indication might have occurred, as maternal depression is a risk factor for developing ASD. This might explain the finding that significant associations disappeared after adjusting for psychiatric diagnosis and, intriguingly, that in comparison with no SSRI exposure, children of women exposed to SSRIs only before pregnancy (which could be considered as a proxy of suffering from depression during pregnancy) were at increased risk of developing ASD. Despite maternal depression being included in the analysis as a confounding variable, information on maternal diagnoses was available only from psychiatric hospitals and psychiatric units, but not from primary care settings, where the majority of cases of maternal depression is expected to be recognised. It is therefore possible that residual confounding by indication might have occurred. A second concern refers to the study cohort. Although it is representative of the Denmark population, it may not be representative of other populations, as shown by the prevalence of pregnancy-related use of SSRIs, which was very low in the present study, as compared, for example, with the USA. The same applies to the prevalence of autism, lower in this study as compared with, for example, the USA.

A third reason for concern is the exposure variable, as the present study employed SSRI prescription as a proxy of SSRI use. The general issue that a relevant proportion of medicines prescribed for people with chronic conditions are not taken might be particularly challenging in this study, as depressed women might decide not to take a prescribed treatment with SSRIs, when pregnant, more often than depressed women who are not pregnant. A final concern is that length of
follow-up was 5–10 years, which means that some children were followed for 10 years after birth while for others follow-up was truncated at 5 years. Considering the relatively high rates of ASD diagnoses in scholar age it is possible that some children were erroneously categorised as non-cases because a diagnosis of ASD was made after 5 years of age. Clearly, it is difficult to speculate on whether this under recognition might have somewhat hampered the analyses.

It is worth noting that, according to the study authors, these results are not conclusive, as an increased risk of ASDs cannot be completely ruled out: on the basis of the upper boundary of the CI of the main analysis (which is 1.61), it cannot be excluded that SSRI exposure increases the relative risk of developing ASDs up to 61%.

CONCLUDING REMARKS

The three studies briefly described in the present commentary outline the value of weighing the potential beneficial effects associated with AD use in pregnancy and postpartum against a number of potentially harmful consequences. This cautious approach should be individualised on a case-by-case basis, employing shared decision-making techniques that involve the mother and experts in psychiatry, obstetrics and gynaecology. It should be recognised that the treatment of women with ADs during pregnancy and postpartum is challenging and complex.

Doctors should be aware that recent data refer almost exclusively to the SSRIs, the most commonly prescribed ADs in Western countries. However, in several low-income and middle-income countries tricyclic and related ADs are still widely prescribed. In addition, in depressed patients with no satisfactory response to the SSRIs, switching to a different AD is a frequent therapeutic option. Thus, AD drugs not belonging to the SSRI class are still widely prescribed globally, and therefore a clearer understanding of whether some of the risks associated with SSRI exposure similarly apply to other AD classes is a public health priority.

In general, treatment guidelines suggest that in women with mild-to-moderate depression without a history of recurrent or severe depression, or women with depression related to specific adjustments or stressors, psychotherapy with a trained provider is a first-line intervention. Women with more severe depression a thorough risk-benefit discussion of ADs in general and the specific medication in particular is warranted, taking into consideration that paroxetine is generally contraindicated. In postpartum depression pharmacological treatment recommendations for women who are lactating must include discussion with the patient regarding the benefits of breastfeeding, risks of AD use during lactation and risks of untreated illness. Doctors should consider that treatment decisions must be guided by the woman’s preference and should be contextualised to local healthcare, social and economic circumstances.

Competing interests None.

doi:10.1136/eb-2014-101884

REFERENCES